Package 69097-875-02

{"route": ["ORAL"], "spl_id": "6fb20e45-74e9-4038-9db0-9eaf24b5560a", "openfda": {"upc": ["0369097875022", "0369097876029"], "unii": ["ZG7E5POY8O"], "rxcui": ["993541", "993557"], "spl_set_id": ["c2cf79d7-1aba-4391-980b-5e218781f7c6"], "manufacturer_name": ["CIPLA USA INC.,"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (69097-875-02)", "package_ndc": "69097-875-02", "marketing_start_date": "20160829"}, {"sample": false, "description": "90 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (69097-875-05)", "package_ndc": "69097-875-05", "marketing_start_date": "20160829"}, {"sample": false, "description": "500 TABLET, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (69097-875-12)", "package_ndc": "69097-875-12", "marketing_start_date": "20160829"}], "brand_name": "Bupropion Hydrochloride (XL)", "product_id": "69097-875_6fb20e45-74e9-4038-9db0-9eaf24b5560a", "dosage_form": "TABLET, EXTENDED RELEASE", "pharm_class": ["Aminoketone [EPC]", "Dopamine Uptake Inhibitors [MoA]", "Increased Dopamine Activity [PE]", "Increased Norepinephrine Activity [PE]", "Norepinephrine Uptake Inhibitors [MoA]"], "product_ndc": "69097-875", "generic_name": "bupropion hydrochloride", "labeler_name": "CIPLA USA INC.,", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Bupropion Hydrochloride", "brand_name_suffix": "(XL)", "active_ingredients": [{"name": "BUPROPION HYDROCHLORIDE", "strength": "150 mg/1"}], "application_number": "ANDA206556", "marketing_category": "ANDA", "marketing_start_date": "20160829", "listing_expiration_date": "20261231"}